Coburg, Bavaria, Germany
I am a board-certified pathologist and senior leader in Pharma, focused on building and scaling digital pathology and AI-enabled platforms in regulated environments. I currently lead digital pathology and process optimization initiatives with responsibility for enterprise pathology infrastructure, CAP accreditation, and the enablement of AI-driven image analysis across R&D and clinical trial applications. My role sits at the intersection of pathology, quality systems, data science, and technology delivery. My work centers on transforming pathology from a diagnostic function into a scalable, data-driven capability—accelerating drug development, improving decision confidence, and reducing operational and regulatory risk within GxP- and CAP-compliant settings. What differentiates me is the ability to translate complex pathology and AI concepts into enterprise-ready solutions, aligning innovation with compliance, robustness, and long-term platform value. I am particularly interested in senior leadership opportunities where pathology and AI are strategic enablers for scalable, regulated innovation. Views expressed are my own
Deputy to the CAP/CLIA Laboratory Director, with delegated responsibility for regulatory readiness, inspection preparedness, and operational quality in CAP/CLIA- and GxP-compliant environments.
I lead transformational change in histology by owning the strategy and execution of digital pathology, AI-enabled image analysis, and process optimization within regulated CAP/CLIA and GxP environments. In my role, I am accountable for enterprise histology and digital pathology infrastructure, the development and scaling of AI and computational pathology capabilities, and cross-functional delivery supporting R&D and clinical trial programs. I lead multidisciplinary teams and work closely with pathology, data science, IT, quality, and translational partners to ensure robust, compliant, and scalable solutions. As a clinical trial and R&D subject matter expert, I support study design and execution through guidance on sample stratification, biomarker analysis, and data interpretation—ensuring high-quality pathology data informs critical research and development decisions. Key areas of responsibility and impact include: + I lead and develop managers and senior individual contributors across histology, digital pathology, and image analysis functions. + Ownership of digital pathology and histology platforms, including infrastructure, validation, and compliance + Development and enablement of AI and computational pathology capabilities in regulated environments + Leadership of process optimization initiatives to improve efficiency, robustness, and scalability + Pathology SME support for clinical trials and R&D programs, including biomarker strategy and data interpretation + Cross-functional leadership across pathology, genomics, diagnostics, translational science, IT, and quality I am focused on positioning histology and pathology as scalable, data-generating platforms that enable innovation while maintaining the highest standards of regulatory rigor.
In my role as a Senior Consultant in Pathology, I specialized in molecular pathology, playing a key role in advancing precision medicine and shaping diagnostic strategies. I led the molecular tumor board, where I facilitated the integration of genomic data into clinical decision-making, collaborating with oncologists and other specialists to optimize patient care. A key aspect of my work was the implementation of IVDR (In Vitro Diagnostic Regulation) for molecular pathology, ensuring compliance with regulatory standards and enhancing the quality and reliability of molecular diagnostics. This involved optimizing workflows, validating assays, and aligning laboratory processes with evolving regulatory requirements. Beyond molecular pathology, I was actively involved in hematopathology, contributing to the diagnosis and classification of hematological malignancies. My expertise also extended to general pathology, ensuring comprehensive diagnostic evaluations across a broad spectrum of diseases. My work bridged cutting-edge molecular diagnostics with traditional pathology, helping to drive personalized treatment approaches and enhance patient outcomes. I was particularly passionate about the evolving role of pathology in precision oncology, the integration of new technologies into routine clinical practice, and the regulatory advancements shaping the future of molecular diagnostics.
During my residency in Pathology, I was trained in all major facets of modern pathology, spanning routine histopathological diagnostics and advanced molecular techniques. Alongside my clinical responsibilities, I provided lectures and practical instruction to medical students and Medical Technical Laboratory Assistants (MTLAs), fostering an environment of continuous learning. In addition, I served as the deputy to the QA lead for ISO EN 17020 compliance. My active involvement in research led to numerous publications, reflecting my dedication to advancing the field and enhancing patient care.
As a biologist, I led a specialized molecular pathology laboratory, successfully implementing RAS and HPV testing protocols under ISO EN 17020 standards.